Hydroxyurea and Cardiac Sequelae in Children with Sickle Cell Disease

Authors

  • Moustafa M. Abdel Raheem Department of Paediatrics, Faculty of Medicine, El-Minya University, El-Minya, Egypt
  • Mohamed A. Abdulrahman Department of Biochemistry, College of Medicine, KKU, Abha, Saudi Arabia

DOI:

https://doi.org/10.13112/pc.477

Keywords:

HYDROXYUREA, HEART, CHILDREN, ANEMIA, SICKLE CELL

Abstract

Cardiac complications in sickle cell disease patients are widely expected. They may be related to iron deposition, anaemia or vasculitis.Hydroxyurea is a known drug that decreases haemoglobin (Hb) S levels. The objective of the study was to assess the effect ofhydroxyurea on cardiac sequelae in children with sickle cell disease. Sixty-five sickle cell disease children were enrolled in the study; 37of them were on regular follow up and hydroxurea treatment, whereas 28 were not. All patients underwent echocardiography andN-terminal pro-brain natriuretic peptide (NT-proBNP) assay. Plasma levels of NTproBNP were significantly lower in sickle cell patientswho were on hydroxyurea treatment than in those without this therapy (p=0.03). NTproBNP levels showed significant correlationswith Hb (r=-0.72, p<0.05) and HbS levels (r=0.54, p<0.05). Significant positive correlations were detected between NTproBNP andechocardiography findings (r=0.64, p<0.01) including left ventricular mass index (r=0.78, p<0.01). In conclusion, hydroxyurea mayreduce cardiac complications in children with sickle cell disease.Key words: HYDROXYUREA; HEART; CHILDREN; ANEMIA, SICKLE CELL

Downloads

Published

2019-03-30

Issue

Section

Article

How to Cite

Raheem, M. M. A., & Abdulrahman, M. A. (2019). Hydroxyurea and Cardiac Sequelae in Children with Sickle Cell Disease. Paediatria Croatica, 63(1), 1-5. https://doi.org/10.13112/pc.477

Similar Articles

1-10 of 167

You may also start an advanced similarity search for this article.